047 What are the predictors of not receiving a reperfusion therapy in STEMI patients?  by Ghérissi, Ismail et al.
© Elsevier Masson SAS. All rights reserved.
 
16 Archives of Cardiovascular Diseases Supplements (2012) 4, 1-29
because of misdiagnosis, late presentation or spontaneous reperfusion. Man-
agement of STEMI has evolved considerably worldwide during the past two
decades.
Aim: To describe the change over time of reperfusion strategy in STEMI
pts among the population of MIRAMI registry. 
Methods: A total of 1318 pts admitted for AMI between January 1995 and
December 2010 were included in our MIRAMI (MonastIR Acute Myocardial
Infarction) registry. We evaluated the change over time of each treatment
strategy during the mentioned study 
The proportion of pts receiving a reperfusion therapy was fluctuating but
relatively stable during the last 16 years ranging from 45.2% in 1995 to 58.2%
in 2010 with a peak of 74.2% in 2001. From 1995 to 2000, reperfusion was
almost exclusively performed by thrombolysis whereas a dramatic increase of
the use of PAMI was observed between 2000 and 2005 followed by a decrease
in favor of the use of thrombolysis during the following 5 years probably due
to an increase of the use of prehospital thrombolysis that ranged from14.3%
in 2001 to 84% in 2009 among the thrombolysed pts. 
Conclusion: In our MIRAMI Registry, the rate of reperfusion therapy was
relatively stable over the 16 year-period of the study. Over all, thrombolysis
was more frequently used than angioplasty except for the period between 2000
and 2005. The most frequently recent use of thrombolysis over angioplasty
was presumably due to an increase of its use in the ambulance. 
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Background: The standard of care for ST-segment elevation myocardial
infarction (STEMI) is prompt coronary reperfusion with primary percutaneous
coronary intervention or thrombolysis .
However, a substantial number of patients (pts) with myocardial infarction
receive only conservative medical management.
The aim of the present study was to examine predictive factors of not
receiving reperfusion therapy among STEMI pts.
Methods and Results: From January 1995 to December 2010, the
MIRAMI Registry enrolled 1318 patients admitted for STEMI. Multivariate
analysis was performed to determine predictors of not receiving reperfusion
therapy. Two hundred eighty nine patients were excluded from this analysis
because of lacking data. The remaining 1029 pts were considered for this anal-
ysis with 360 (35%) that received a reperfusion therapy and 669 (56%) that
were treated conservatively. Multivariate analysis identified only three inde-
pendent predictors for not receiving a reperfusion therapy: age 75 years
(p=0.004), time to hospital admission -6 hours from the onset of symptoms
(p<0.001) and night (from 08:00 PM to 08:00 AM) occurrence (p=0.004).
Conclusions: More than half of the population of this study did not receive
a reperfusion therapy. Elderly, female patients, late presenters and patients
who present at night are more likely to not receive a reperfusion therapy. 
Results:
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Objectives and background: Specific data about clopidogrel response in
elderly patients are lacking. The present study was performed to compare platelet
reactivity and clopidogrel response between elderly patients (> 75 yrs) and
younger patients (< 75 yrs) undergoing Percutaneous Coronary Intervention (PCI)
for Non ST segment Elevation Acute Coronary Syndrome (NSTE ACS). 
Methods: 689 patients were enrolled, including 162 elderly and 527
younger patients. All patients received loading dose of 600 mg of clopidogrel
followed by 150 mg daily. Post-treatment platelet reactivity was assessed by
ADP 10 μmol/L-induced platelet aggregation (ADP-Ag) and specific pharma-
cological response to clopidogrel by the Platelet Reactivity Index VASP (PRI
VASP). High Post-treatment platelet Reactivity (HPR) was defined as ADP-
Ag >70%. Clinical events were recorded during one month Follow-Up (FU).
Results: Elderly patients had a higher rate of both ischemic and bleeding
complications (p=0.04 and 0.03 respectively). Post-treatment platelet reac-
tivity in response to both loading and maintenance clopidogrel doses was
higher in elderly than in younger patients: 50±17% vs. 45±17%, p=0.002; and
57±15% vs. 53±16%, p=0.0005, respectively. The rate of HPR was signifi-
cantly higher in elderly patients after 600 mg and 150 mg: 14% vs. 9%,
p=0.04; and 23% vs. 15%, p=0.02, respectively. Conversely, pharmacological
response to clopidogrel was not impaired in elderly patients after loading and
maintenance doses: 43±21% vs. 46±21%, p=0.17 and 38±18% vs. 39±18,
p=0.55, respectively. 
Conclusion: Elderly patients have an impaired prognosis after ACS. They dis-
play higher post-treatment platelet reactivity. However, this higher platelet reac-
tivity does not seem to be related to impaired specific response to clopidogrel.
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Cardiovascular diseases are the leading cause of mortality in patients with
end stage renal disease (ESRD). A positive non invasive test for myocardial
P CI
Age 0.004 0.973-0.995
Hospital admission=6 hours <0.001 0.066-0.187
Night occurrence 0.004 0.236-0.766
Female sex 0.059 0.49-1.01
Serum creatinin=150 μmol/l 0.936 0.62-1.66
